Ask about this productRelated genes to: AHCY protein
- Gene:
- AHCY NIH gene
- Name:
- adenosylhomocysteinase
- Previous symbol:
- -
- Synonyms:
- SAHH
- Chromosome:
- 20q11.22
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2018-05-03
Related products to: AHCY protein
Related articles to: AHCY protein
- Nasopharyngeal carcinoma (NPC) is a widely prevalent malignant tumor with a marked tendency toward metastasis and recurrence. Ferroptosis-related genes (FRGs) are critically involved in the pathogenesis of NPC. This study aims to employ bioinformatics analysis methods to identify key genes influencing the malignant progression of NPC and to investigate the regulatory mechanisms of these genes. - Source: PubMed
Publication date: 2026/02/25
Zheng HuizhenWang XiaodanChen Qin - Colorectal cancer (CRC) is a major cause of morbidity and mortality, with chronic inflammation from inflammatory bowel disease (IBD) representing a well-established risk factor. Clarifying shared molecular mechanisms may facilitate early detection and prevention strategies. - Source: PubMed
Dhami JaiyaRadhakrishnan Swarnima KollampallathRuss DominicMondal SudipAlzarooni AbdulrahmanMerodio Laura BravoDuggal Niharika AGupta RuchiAcharjee Animesh - Acute coronary syndrome, driven by vulnerable plaque (VP) instability, is a major cause of cardiovascular mortality. Current diagnostic methods for VPs are limited by invasiveness or low specificity, highlighting the need for non-invasive biomarkers. Using single-cell RNA sequencing (scRNA-seq) of peripheral blood mononuclear cells (PBMCs) from coronary artery disease (CAD) patients with VPs and controls, we identified circulating T cell-platelet aggregates (TPAs) significantly enriched in VP patients and linked to plaque instability via pro-inflammatory pathways. Through high dimensional weighted gene co-expression network analysis, we discovered TPAs' hub genes and demonstrated their role in plaque destabilization. Furthermore, employing machine learning, including Boruta, least absolute shrinkage and selection operator (LASSO) regression and support vector machine-recursive feature elimination (SVM-RFE), we screened for five blood biomarkers that can serve as diagnostic indicators for VPs. Our study demonstrates that TPAs are critically involved in VPs formation. Furthermore, we identified EPHB6, STAT1, RPL23, IKZF3 and AHCY as potential circulating biomarkers for non-invasive detection of VPs. - Source: PubMed
Publication date: 2026/02/04
Yao DiruMeng PeinaHuang BinWu RongrongLin ZihanLi KeningWu LingxiangXia PengLiu QuanzhongWu WeiWang ShukuiWang QianghuYe Fei - S-Adenosylhomocysteinase (AHCY, also known as SAHH) is a highly conserved enzyme that catalyzes the reversible hydrolysis of SAH into adenosine and homocysteine. As the sole enzyme capable of catalyzing this reaction, AHCY modulates cellular methylation potential required for DNA, RNA, and protein methyltransferase activity. Recent discoveries, however, expand its role well beyond this canonical function, positioning AHCY as a metabolic gatekeeper that integrates one-carbon metabolism with epigenetic regulation, RNA processing, nucleotide balance, and redox signaling. This review brings together mechanistic, structural, and regulatory insights into AHCY while critically evaluating diverse biochemical and biophysical methods for assaying its activity. Comparative structural analyses uncover conserved tetrameric organization alongside species-specific adaptations in oligomeric state, NAD pocket accessibility, and C-terminal dynamics that shape enzyme catalytic efficiency and regulation. AHCY function is further fine-tuned through a wide spectrum of posttranslational modifications and small-molecule interactions, linking it to transcriptional control, stress adaptation, and viral infection. By linking SAH turnover to methylation capacity and adenosine/homocysteine flux, AHCY coordinates metabolism with chromatin regulation and stress responses. These cross-cutting roles highlight how a single metabolic enzyme bridges catalysis, regulation, and disease. In doing so, AHCY exemplifies the broader principle that metabolic enzymes can have a central role as regulators of metabolic flux and cellular regulation, offering both mechanistic depth and translational promise as a therapeutic target. - Source: PubMed
Publication date: 2026/02/02
Stanhope Sarah CWeake Vikki M - Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD) characterised by high prevalence, increasing incidence among younger individuals and poor prognosis. NASH pathophysiology is not completely understood, and at present, there are no viable pharmacological treatments for this condition in clinical practice. Gentiopicroside (GPS). Can alleviate NASH by reducing inflammatory responses, inhibiting oxidative stress and influencing blood lipid levels. - Source: PubMed
Publication date: 2026/01/06
Chen JiaxinZuo HuilingJiao YuhangZhao HuanhuanMa XuanXiao YahuiLi XiangqiongZhao WeiShi AnhuaChen Wenhui